← SynDRA
GANCICLOVIR
SynDRA canonical compound SYN0006444 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | DNA polymerase inhibitor |
|---|
| Indication | cytomegalovirus (CMV) |
|---|
| Disease area | infectious disease |
|---|
All known targets
- GRM1
- GRM5
- HSV UL30
- TK
- UL26
- VCP
- punA
Mechanisms of action (all sources)
- DNA polymerase inhibitor
- Inhibitor
Drug classes
- DNA Polymerase Inhibitors
- Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
- Nucleoside Analog Antiviral
- Anti-Infective Agents
- Antiviral Agents
ATC classes
- S01A · ANTIINFECTIVES
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- denosine
- gancyclovir
- hydroxyacyclovir
- natclovir
- ganciclovir sodium
- Gancyclovir
- BW-759U
- NSC-759656
- RS-21592
- Cymevene
- Cytovene
- Ganzyk-rtu
- Virgan
- Vitrasert
- Vitrasert implant
- Zirgan
- Valganciclovir hydrochloride impurity a
- Hydroxyacyclovir
- Ganciclovirum
- HHEMG
- BIOLF-62
- BW 759U
- Ganciclovirum [Latin]
- 2'-NDG
- 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one
- 2'-Nor-2'-deoxyguanosine
- 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
- BW-B 759U
- UNII-P9G3CKZ4P5
- DRG-0018
- BW 759
- 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
- 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
- CCRIS 9212
- GA2
- Cytovene-IV
- HSDB 6512
- ganciclovir (ep impurity)
Reported adverse events
- Granulocytopenia
- TEN
- Chills
- Leukopenia
- Neutropenia
- Retinal detachment
- Sepsis
- Stevens-Johnson syndrome
- Thrombocytopenia
- Vomiting
- Hyperhidrosis
- Pruritus
Look up GANCICLOVIR in the interactive SynDRA portal →